Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Bak

Showing results (51-60 of 62) with videos related to

Pageof 7
Sort By:
Scientific Reports|March 10, 2017
Genomic Analyses of Breast Cancer Progression Reveal Distinct Routes of Metastasis EmergenceAnne Bruun Krøigård, Martin Jakob Larsen, Charlotte Brasch-Andersen, et al.
Journal of the American Chemical Society|October 30, 2018
Genetic Incorporation of Olefin Cross-Metathesis Reaction Tags for Protein ModificationBhaskar Bhushan, Yuya A Lin, Martin Bak, et al.
NPJ Precision Oncology|September 24, 2022
Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancerAbeer J Al-Qasem, Carla L Alves, Sidse Ehmsen, et al.
Plos One|May 25, 2013
Classifications within molecular subtypes enables identification of BRCA1/BRCA2 mutation carriers by RNA tumor profilingMartin J Larsen, Torben A Kruse, Qihua Tan, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|May 5, 2024
HER2-targeted, enzyme-activated liposomes show superior in vivo efficacy in an ovarian cancer modelChristian Ammitzbøll Juul, Trine Bjørnbo Engel, Frederikke Petrine Fliedner, et al.
Frontiers in Oncology|February 11, 2025
RET inhibition overcomes resistance to combined CDK4/6 inhibitor and endocrine therapy in ER+ breast cancerCharlotte K Kindt, Sidse Ehmsen, Sofie Traynor, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 30, 2025
Micellar formulation provides potent and tolerable TLR7 agonist treatment for anti-cancer immunotherapyEsben Christensen, Camilla Stavnsbjerg, Rasmus Münter, et al.
Nature Communications|September 17, 2021
Publisher Correction: Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancerCarla L Alves, Sidse Ehmsen, Mikkel G Terp, et al.
Nature Communications|August 26, 2021
Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancerCarla L Alves, Sidse Ehmsen, Mikkel G Terp, et al.
Springerplus|April 6, 2013
The combination of Ki67, histological grade and estrogen receptor status identifies a low-risk group among 1,854 chemo-naïve women with N0/N1 primary breast cancerCarina Strand, Martin Bak, Signe Borgquist, et al.
Pageof 7

Showing results (51-60 of 62) with videos related to

Sort By:
Pageof 7
Scientific Reports|March 10, 2017
Genomic Analyses of Breast Cancer Progression Reveal Distinct Routes of Metastasis EmergenceAnne Bruun Krøigård, Martin Jakob Larsen, Charlotte Brasch-Andersen, et al.
Journal of the American Chemical Society|October 30, 2018
Genetic Incorporation of Olefin Cross-Metathesis Reaction Tags for Protein ModificationBhaskar Bhushan, Yuya A Lin, Martin Bak, et al.
NPJ Precision Oncology|September 24, 2022
Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancerAbeer J Al-Qasem, Carla L Alves, Sidse Ehmsen, et al.
Plos One|May 25, 2013
Classifications within molecular subtypes enables identification of BRCA1/BRCA2 mutation carriers by RNA tumor profilingMartin J Larsen, Torben A Kruse, Qihua Tan, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|May 5, 2024
HER2-targeted, enzyme-activated liposomes show superior in vivo efficacy in an ovarian cancer modelChristian Ammitzbøll Juul, Trine Bjørnbo Engel, Frederikke Petrine Fliedner, et al.
Frontiers in Oncology|February 11, 2025
RET inhibition overcomes resistance to combined CDK4/6 inhibitor and endocrine therapy in ER+ breast cancerCharlotte K Kindt, Sidse Ehmsen, Sofie Traynor, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 30, 2025
Micellar formulation provides potent and tolerable TLR7 agonist treatment for anti-cancer immunotherapyEsben Christensen, Camilla Stavnsbjerg, Rasmus Münter, et al.
Nature Communications|September 17, 2021
Publisher Correction: Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancerCarla L Alves, Sidse Ehmsen, Mikkel G Terp, et al.
Nature Communications|August 26, 2021
Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancerCarla L Alves, Sidse Ehmsen, Mikkel G Terp, et al.
Springerplus|April 6, 2013
The combination of Ki67, histological grade and estrogen receptor status identifies a low-risk group among 1,854 chemo-naïve women with N0/N1 primary breast cancerCarina Strand, Martin Bak, Signe Borgquist, et al.
Pageof 7